Anzeige
Mehr »
Login
Mittwoch, 01.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E27P | ISIN: CA30053H1055 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
EVOME MEDICAL TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
EVOME MEDICAL TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
215 Leser
Artikel bewerten:
(1)

Evome Medical Technologies Inc.: Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") announces the appointment of two senior healthcare executives to its Board of Directors.?

Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive ?member of the Board of Directors.?

Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors.

In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.

?"Now that we have successfully executed on our turnaround plan, I am pleased to have Wayne and Bill join the ?Board," said Mike Seckler, CEO of Evome. "I worked with both of these talented and successful healthcare executives for many years while at Ferring and I am eager to benefit from their valuable guidance and expertise, ?particularly in the realms of product launch and commercialization. Dr. Kashkin's contributions will play a crucial role in advancing our innovation and development strategies, aligning with our vision to democratize our ?Biodex Brands. I can now say we have completed all of the necessary steps to transform our company. We ?have driven revenue growth, developed new products, cut costs and restructured our debt. The final step was ?to add some seasoned talent to our Board to assist us in driving shareholder value."?

For more information please contact:?

Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826?
Email: info@evomemedical.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ?policies of ??the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ?release.?


Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.